CpG-ODN and Coa-ASC16 |
|
Vaxjo ID |
385 |
|
Vaccine Adjuvant Name |
CpG-ODN and Coa-ASC16 |
|
Alternative Names |
CpG-ODN stands for "cytosine-phosphate-guanine oligodeoxynucleotides." Coa-ASC16 refers to "6-O-ascorbyl palmitate ester." |
|
Adjuvant VO ID |
VO_0005667
|
|
Description |
CpG-ODN are synthetic oligodeoxynucleotides that contain unmethylated cytosine-guanine motifs, which act as immune stimulants. Coa-ASC16 is a nanostructure formed by the self-assembly of 6-O-ascorbyl palmitate ester, which enhances the delivery and efficacy of CpG-ODN. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
To this aim, we formulated class-B synthetic oligodeoxynucleotide containing unmethylated cytosine-guanine motifs (CpG-ODN) with a nanostructure (Coa-ASC16 or coagel) formed by self-assembly of 6-0-ascorbyl palmitate ester. |
|
Structure |
CpG-ODN consists of a backbone of deoxyribonucleic acid with specific cytosine and guanine bases arranged in a particular sequence. Coa-ASC16 is composed of an ascorbic acid polar headgroup attached to a palmitic acid nonpolar hydrocarbon chain. |
|
Appearance |
The appearance of CpG-ODN is typically as a solution, while Coa-ASC16 is described as a nanostructured gel. |
|
Preparation |
CpG-ODN is prepared as a synthetic oligonucleotide, while Coa-ASC16 is formulated by dissolving 6-O-ascorbyl palmitate ester in a dextrose solution and subjecting it to a heating-cooling process. |
|
Dosage |
The article states that the dose of CpG-ODN used in experiments was 75 ug/mouse/dose, but specific dosage information for Coa-ASC16 is not provided. |
|
Function |
we formulated class-B synthetic oligodeoxynucleotide containing unmethylated cytosine-guanine motifs (CpG-ODN) with a nanostructure (Coa-ASC16 or coagel) formed by self-assembly of 6-0-ascorbyl palmitate ester.Coa-ASC16 promoted co-uptake of OVA and CpG-ODN by dendritic cells. The CD8+ T-cell response induced by OVA/CpG-ODN/Coa-ASC16 was dependent of type I interferons and independent of CD4+ T-cells, and showed polyfunctionality and efficiency against an intracellular pathogen. |
|
Safety |
The article indicates that Coa-ASC16 did not induce toxic systemic effects in preclinical studies, suggesting a favorable safety profile, but specific safety data for CpG-ODN are not detailed. |
| References |
Chiodetti et al., 2018: Chiodetti AL, Sánchez Vallecillo MF, Dolina JS, Crespo MI, Marin C, Schoenberger SP, Allemandi DA, Palma SD, Pistoresi-Palencia MC, Morón G, Maletto BA. Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4(+) T Cell-Independent CD8(+) T-Cell Response Against Unconjugated Protein Antigen. Frontiers in immunology. 2018; 9; 2319. [PubMed: 30364187].
|
